General Pharmacology — MCQs

General Pharmacology Indian Medical PG Practice Questions and MCQs

Question 221: Drugs that require a prescription from a registered medical practitioner for dispensing are included in which schedule?

A. Schedule C
B. Schedule E
C. Schedule H (Correct Answer)
D. Schedule I

Explanation: **Explanation:** The correct answer is **Schedule H**. Under the Drugs and Cosmetics Rules (1945), drugs are categorized into various schedules based on their storage, sale, and dispensing requirements. **1. Why Schedule H is correct:** Schedule H contains a list of prescription drugs that cannot be sold over the counter (OTC). They must be dispensed only upon the production of a valid prescription from a **Registered Medical Practitioner (RMP)**. The label of these drugs must carry the symbol **'Rx'** and a warning stating: *"To be sold by retail on the prescription of a Registered Medical Practitioner only."* **2. Analysis of Incorrect Options:** * **Schedule C:** Relates to **Biological and Special Products** (e.g., sera, vaccines, insulin, and parenteral antibiotics) which have specific storage and import regulations. * **Schedule E:** Deals with a list of **Poisonous substances** under the Ayurvedic, Siddha, and Unani systems of medicine. * **Schedule I:** This is a distractor; it is not a standard functional schedule for drug dispensing in the current Indian regulatory context (unlike Schedule G or X). **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Schedule H1:** Introduced in 2013 to curb the misuse of **antibiotics** and anti-TB drugs. It requires the pharmacist to maintain a separate register with patient and prescriber details, kept for 3 years. * **Schedule X:** Includes **Psychotropic and Narcotic drugs** (e.g., Ketamine, Amphetamines). These require a double-copy prescription, and the pharmacist must retain one copy for 2 years. * **Schedule G:** Drugs that require **medical supervision** but not necessarily a formal prescription for every refill (e.g., Metformin, Antihistamines). They carry the warning: *"Caution: It is dangerous to take this preparation except under medical supervision."*

Question 222: Therapeutic drug monitoring is indicated for which of the following drugs?

A. Phenytoin
B. Metformin (Correct Answer)
C. Tacrolimus
D. Cyclosporin

Explanation: **Explanation:** Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring drug concentrations in the blood to maintain a constant concentration within a specific **therapeutic window**. It is typically indicated for drugs with a narrow therapeutic index, unpredictable pharmacokinetics, or a direct correlation between plasma levels and toxicity/efficacy. **Why Metformin is the Correct Answer (in the context of "NOT indicated"):** *Note: There appears to be a typographical error in the provided key. In clinical pharmacology, **Metformin does NOT require TDM**.* Its efficacy is monitored by blood glucose levels and HbA1c, and its primary serious side effect (lactic acidosis) is not strictly dose-dependent or easily predicted by plasma levels. Therefore, if the question asks which drug is **NOT** indicated for TDM, Metformin is the correct choice. **Analysis of Other Options (Drugs that REQUIRE TDM):** * **Phenytoin (Option A):** Requires TDM because it exhibits **zero-order (saturation) kinetics** even at therapeutic doses. Small dose increments can lead to disproportionately large increases in plasma levels and toxicity. * **Tacrolimus (Option C) & Cyclosporin (Option D):** Both are calcineurin inhibitors used in organ transplants. They have a **narrow therapeutic index** and highly variable inter-individual pharmacokinetics. Sub-therapeutic levels lead to graft rejection, while supra-therapeutic levels cause nephrotoxicity. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for TDM drugs:** "**L**ithium, **T**heophylline, **P**henytoin, **D**igoxin, **A**minoglycosides, **I**mmunosuppressants (Cyclosporin/Tacrolimus), **V**alproate" (**L**et **T**he **P**eople **D**ecide **A**bout **I**ndividual **V**ictory). * **TDM is NOT needed for:** Drugs with a wide therapeutic index (e.g., Penicillin), drugs whose effect is easily measured (e.g., Warfarin via PT/INR, Antihypertensives via BP), and "hit-and-run" drugs (e.g., Omeprazole).

Question 223: Which of the following acts on nuclear receptors?

A. GABA
B. Insulin
C. Alpha-1 receptor
D. Thyroxine (Correct Answer)

Explanation: **Explanation:** The correct answer is **Thyroxine (D)**. Receptors are classified based on their location and mechanism of action. **Nuclear receptors** are intracellular receptors that act as ligand-activated transcription factors. To reach these receptors, a drug must be lipid-soluble to cross the cell membrane. * **Thyroxine (T4/T3):** Although thyroid hormones are amino acid derivatives, they enter the cell via specific transporters and bind to receptors located directly on the **nucleus**. Once bound, they alter gene transcription, leading to the synthesis of new proteins. Other examples of drugs acting on intracellular/nuclear receptors include Steroids (Glucocorticoids, Mineralocorticoids, Sex hormones), Vitamin A, and Vitamin D. **Why other options are incorrect:** * **GABA (A):** Acts on **Ionotropic receptors** (GABA-A is a ligand-gated chloride channel) or Metabotropic receptors (GABA-B is G-protein coupled). * **Insulin (B):** Acts on **Enzyme-linked receptors** (specifically, Receptor Tyrosine Kinase) located on the cell membrane. * **Alpha-1 receptor (C):** This is a **G-Protein Coupled Receptor (GPCR)**, specifically the Gq subtype, which works via the IP3-DAG second messenger pathway. **High-Yield NEET-PG Pearls:** 1. **Fastest acting receptors:** Ion channels (milliseconds), e.g., Nicotinic ACh receptors. 2. **Slowest acting receptors:** Nuclear receptors (hours to days), as they require gene transcription and protein synthesis. 3. **Mnemonic for Cytoplasmic vs. Nuclear:** Most steroids bind in the **C**ytoplasm (except Estrogen/Thyroid), while **T**hyroid, **E**strogen, **V**itamin A & D bind directly in the **N**ucleus (**TEN**).

Question 224: Which of the following terms best describes a drug that blocks the action of adrenaline at its receptors by occupying those receptors without activating them?

A. Pharmacologic antagonist (Correct Answer)
B. Non-competitive antagonist
C. Physiologic antagonist
D. Chemical antagonist

Explanation: **Explanation:** The question describes a drug that binds to the same receptor as an agonist (adrenaline) but fails to trigger a biological response, thereby preventing the agonist from binding. **1. Why Option A is Correct:** A **Pharmacologic Antagonist** is a drug that has **affinity** for a specific receptor but lacks **intrinsic activity** (efficacy = 0). By occupying the receptor site, it prevents the endogenous ligand (like adrenaline) from activating the receptor. This is the classic definition of receptor-level antagonism. **2. Why Other Options are Incorrect:** * **B. Non-competitive Antagonist:** While this is a type of pharmacologic antagonist, it usually binds to an allosteric site or irreversibly to the active site, preventing the agonist from producing a maximal effect regardless of concentration. The question describes the general mechanism of receptor occupation, which is best categorized under the broader term "Pharmacologic Antagonist." * **C. Physiologic Antagonist:** This involves two drugs acting on **different receptors** to produce opposite effects in the same system (e.g., Adrenaline causing bronchodilation via $\beta_2$ vs. Histamine causing bronchoconstriction via $H_1$). * **D. Chemical Antagonist:** This occurs when two substances react in solution, leading to the inactivation of the drug without involving a receptor (e.g., Chelating agents like EDTA binding to lead, or Protamine neutralizing Heparin). **NEET-PG High-Yield Pearls:** * **Competitive Antagonism:** Shifts the Dose-Response Curve (DRC) to the **right** (increases $K_m/EC_{50}$); maximal response remains unchanged. It can be overcome by increasing agonist concentration. * **Non-competitive Antagonism:** Flattens the DRC (decreases $V_{max}$); maximal response is reduced. It cannot be overcome by more agonist. * **Inverse Agonist:** Binds to the same receptor but produces an effect **opposite** to that of the agonist (e.g., Beta-carbolines at GABA receptors).

Question 225: Which drug has a narrow therapeutic range?

A. Lithium (Correct Answer)
B. Sertraline
C. Reboxetine
D. Dothiepin

Explanation: **Explanation:** The **Therapeutic Index (TI)** is the ratio between the dose that produces toxicity and the dose that produces the desired therapeutic effect ($TI = TD_{50} / ED_{50}$). Drugs with a **narrow therapeutic range** have a small margin of safety, meaning minor changes in dosage or blood concentration can lead to therapeutic failure or severe toxicity. **1. Why Lithium is Correct:** Lithium is the classic example of a drug with a very narrow therapeutic index. Its therapeutic serum levels for acute mania are **0.8–1.2 mEq/L**, while toxicity can manifest at levels as low as **1.5 mEq/L**. Because the therapeutic dose is very close to the toxic dose, patients require mandatory **Therapeutic Drug Monitoring (TDM)** to ensure safety and efficacy. **2. Why the Other Options are Incorrect:** * **Sertraline:** An SSRI (Selective Serotonin Reuptake Inhibitor). SSRIs have a wide therapeutic index and are much safer in overdose compared to older antidepressants. * **Reboxetine:** A selective Norepinephrine Reuptake Inhibitor (NRI). It generally has a favorable safety profile and does not require routine blood monitoring. * **Dothiepin (Dosulepin):** A Tricyclic Antidepressant (TCA). While TCAs are more cardiotoxic in overdose than SSRIs, they still possess a wider therapeutic window than Lithium and do not require routine TDM. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Narrow Therapeutic Index drugs:** "**W**ith **L**ow **T**herapeutic **I**ndex, **P**atients **G**et **D**angerous" (**W**arfarin, **L**ithium, **T**heophylline/Tricyclic Antidepressants, **I**mmunosuppressants (Cyclosporine), **P**henytoin/Phenobarbitone, **G**entamicin/Glycosides (Digoxin), **D**igoxin). * **Lithium Monitoring:** Samples for TDM should be collected **12 hours after the last dose** (trough levels). * **Factors increasing Lithium toxicity:** Hyponatremia, dehydration, and drugs like NSAIDs, Thiazides, and ACE inhibitors (which decrease lithium clearance).

Question 226: Sulfonamides inhibit bacterial synthesis of folic acid by:

A. Uncompetitive inhibition.
B. Allosteric inhibition.
C. Competitive inhibition. (Correct Answer)
D. Non-competitive inhibition.

Explanation: **Explanation:** **1. Why Competitive Inhibition is Correct:** Sulfonamides are structural analogs of **Para-Aminobenzoic Acid (PABA)** [1], [2], [3]. In the bacterial folic acid synthesis pathway, the enzyme **Dihydropteroate Synthase** normally utilizes PABA to produce dihydrofolic acid [2]. Because sulfonamides closely resemble PABA, they compete for the same active site on the enzyme [1], [2]. This is a classic example of **competitive inhibition**, which can be reversed by increasing the concentration of the substrate (PABA). Since bacteria must synthesize their own folic acid (unlike humans who absorb it from diet), this inhibition leads to "thymineless death" of the bacteria [1], [3]. **2. Why Other Options are Incorrect:** * **Uncompetitive Inhibition:** The inhibitor binds only to the enzyme-substrate (ES) complex, not the free enzyme. Sulfonamides bind to the free enzyme. * **Allosteric/Non-competitive Inhibition:** These involve binding to a site other than the active site (allosteric site), causing a conformational change. Sulfonamides specifically target the active site where PABA binds [1], [2]. **3. NEET-PG Clinical Pearls & High-Yield Facts:** * **Synergy:** Sulfonamides are often combined with **Trimethoprim** (e.g., Co-trimoxazole) to achieve **sequential blockade** [1], [2], [3]. Trimethoprim inhibits the next step in the pathway: *Dihydrofolate Reductase (DHFR)* [1], [3]. * **Selectivity:** Humans are unaffected because we lack dihydropteroate synthase and utilize preformed folic acid via active transport [3]. * **Resistance:** Bacteria develop resistance by increasing PABA production or altering the enzyme's affinity [3]. * **Adverse Effects:** Watch for **Stevens-Johnson Syndrome (SJS)**, Kernicterus in newborns, and Crystalluria (prevented by alkalinizing urine).

Question 227: Which pharmacological feature is similar for both a "me-too drug" and a prototype drug?

A. Mechanism of action (Correct Answer)
B. Absorption
C. Metabolism
D. Elimination

Explanation: ### Explanation **1. Why "Mechanism of Action" is Correct:** A **prototype drug** is the first drug developed within a specific pharmacological class that serves as the standard for comparison (e.g., Propranolol for beta-blockers). A **"me-too drug"** is a subsequent pharmaceutical agent that is structurally very similar to the prototype. By definition, me-too drugs belong to the same chemical or pharmacological class; therefore, they share the **same mechanism of action** (e.g., Atenolol and Metoprolol are me-too drugs of Propranolol; all act by blocking beta-adrenergic receptors). **2. Why Other Options are Incorrect:** * **B, C, and D (Pharmacokinetics):** The primary purpose of developing me-too drugs is often to improve upon the **pharmacokinetic profile** of the prototype. * **Absorption:** A me-too drug may have better oral bioavailability. * **Metabolism:** It may be designed to avoid first-pass metabolism or have fewer drug-drug interactions (e.g., avoiding the CYP450 system). * **Elimination:** It may have a longer half-life ($t_{1/2}$) allowing for once-daily dosing compared to the prototype’s multiple daily doses. **3. High-Yield Clinical Pearls for NEET-PG:** * **Advantages of Me-too Drugs:** They provide therapeutic alternatives for patients who do not tolerate the prototype, often have improved potency, better safety profiles, or more convenient dosing schedules. * **Economic Impact:** They introduce market competition, which can lower the cost of medications within a class. * **Classic Example:** Cimetidine was the prototype $H_2$ blocker, but me-too drugs like Ranitidine and Famotidine became more popular due to fewer side effects and better potency.

Question 228: Which of the following actions is not caused by H1 receptor?

A. Vasoconstriction
B. Gastric acid secretion (Correct Answer)
C. Increased capillary permeability
D. Bronchoconstriction

Explanation: ### Explanation The physiological actions of Histamine are mediated through four types of G-protein coupled receptors (H1, H2, H3, and H4) [1]. Understanding their distribution is key to solving this question. **Why Gastric Acid Secretion is the correct answer:** Gastric acid secretion is exclusively mediated by **H2 receptors** located on the parietal cells of the stomach [1]. Activation of H2 receptors increases intracellular cAMP, leading to the activation of the proton pump ($H^+/K^+$ ATPase). Therefore, H1 blockers have no effect on acid secretion; this requires H2 blockers like Ranitidine or Famotidine. **Analysis of Incorrect Options:** * **Vasoconstriction (Option A):** While histamine primarily causes vasodilation (via NO release), H1 receptors on vascular smooth muscle can cause **vasoconstriction** in certain vessels (like large arteries) [2]. *Note: In the context of "Triple Response," H1 causes vasodilation.* * **Increased Capillary Permeability (Option B):** H1 receptors cause contraction of endothelial cells in post-capillary venules, leading to gap formation and protein/fluid leakage (exudation) [2]. This results in **edema** and the "wheal" component of the triple response. * **Bronchoconstriction (Option D):** H1 receptors are located on bronchial smooth muscle [1]. Their activation causes potent bronchoconstriction, which is why histamine is contraindicated in asthmatic patients [2]. **NEET-PG High-Yield Pearls:** 1. **Receptor Coupling:** H1 is **Gq**-coupled (IP3/DAG pathway), while H2 is **Gs**-coupled (cAMP pathway) [1]. 2. **Triple Response of Lewis:** Consists of **Flush** (local vasodilation), **Flare** (axonal reflex vasodilation), and **Wheal** (increased permeability)—all primarily H1-mediated. 3. **H1 Antagonists:** First-generation H1 blockers (e.g., Diphenhydramine) are sedative and have anticholinergic effects; second-generation (e.g., Cetirizine) are non-sedating as they do not cross the BBB [1].

Question 229: Which of the following facts is false regarding halothane?

A. It is a pleasant smelling gas
B. It has no effect on vagal tone (Correct Answer)
C. It sensitizes the myocardium to catecholamines
D. It can cause postoperative hepatitis

Explanation: **Explanation:** Halothane is a potent volatile anesthetic agent. The statement that it has no effect on vagal tone is **false** because halothane actually **increases vagal tone**, which frequently leads to **bradycardia**. This vagomimetic effect is a characteristic feature of halothane and can be countered by pre-medication with atropine. **Analysis of Options:** * **Option A (Correct Fact):** Halothane is a non-flammable, non-irritating, and **pleasant-smelling** liquid. Its non-pungent nature makes it an excellent choice for smooth inhalation induction, especially in pediatric patients. * **Option C (Correct Fact):** Halothane **sensitizes the myocardium to catecholamines** (epinephrine/norepinephrine). This significantly increases the risk of ventricular arrhythmias, especially if exogenous adrenaline is administered during surgery. * **Option D (Correct Fact):** Halothane undergoes significant hepatic metabolism (up to 20%). A reactive metabolite (trifluoroacetylated protein) can trigger an immune-mediated reaction leading to **Halothane Hepatitis**, typically occurring postoperatively. **High-Yield NEET-PG Pearls:** 1. **Malignant Hyperthermia:** Halothane is a known trigger (Treatment: Dantrolene). 2. **Uterine Effect:** It causes significant uterine relaxation, which can lead to postpartum hemorrhage (PPH); hence, it is avoided during labor. 3. **Blood-Gas Partition Coefficient:** It has a relatively high coefficient (~2.3), leading to slower induction and recovery compared to Sevoflurane or Desflurane. 4. **Cerebral Effect:** It is a potent cerebral vasodilator, which can increase intracranial pressure (ICP).

Question 230: Phocomelia is an adverse effect due to which of the following teratogens?

A. Thalidomide (Correct Answer)
B. Warfarin
C. Enalapril
D. Phenytoin

Explanation: **Explanation:** **Thalidomide (Correct Answer):** Phocomelia is a classic teratogenic manifestation characterized by "seal-like limbs," where the long bones of the limbs are absent or significantly shortened, and the hands/feet are attached directly to the trunk. Thalidomide, originally used as a sedative and anti-emetic for morning sickness in the 1950s, was found to inhibit angiogenesis (via inhibition of bFGF and VEGF) and cause oxidative stress during the critical period of limb development (days 24–36 of gestation). **Analysis of Incorrect Options:** * **Warfarin:** Causes **Fetal Warfarin Syndrome**, characterized by nasal hypoplasia, stippled epiphyses (chondrodysplasia punctata), and CNS defects. It does not cause phocomelia. * **Enalapril (ACE Inhibitors):** These are associated with **fetal renal dysgenesis**, oligohydramnios, and skull ossification defects. They are contraindicated especially in the 2nd and 3rd trimesters. * **Phenytoin:** Causes **Fetal Hydantoin Syndrome**, which presents with craniofacial abnormalities (cleft lip/palate), microcephaly, and hypoplastic phalanges/nails. **High-Yield Clinical Pearls for NEET-PG:** * **Thalidomide's current use:** Despite its history, it is now used for Erythema Nodosum Leprosum (ENL) and Multiple Myeloma due to its immunomodulatory and anti-angiogenic properties. * **Critical Period:** Teratogens typically have the most profound effect during **organogenesis** (weeks 3 to 8 of gestation). * **Other limb defects:** Sodium Valproate is specifically linked to neural tube defects, while Lithium is linked to **Ebstein’s anomaly** (tricuspid valve defect).

Practice by Chapter

Pharmacokinetics: Absorption and Distribution

Practice Questions

Pharmacokinetics: Metabolism and Excretion

Practice Questions

Pharmacodynamics and Receptor Theory

Practice Questions

Drug-Receptor Interactions and Dose-Response

Practice Questions

Pharmacogenetics and Personalized Medicine

Practice Questions

Adverse Drug Reactions and Toxicity

Practice Questions

Drug Interactions

Practice Questions

Drug Development and Regulation

Practice Questions

Pediatric and Geriatric Pharmacology

Practice Questions

Placental Transfer and Lactation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free